Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Allergopharma Joachim Ganzer KG |
---|---|
Information provided by: | Allergopharma Joachim Ganzer KG |
ClinicalTrials.gov Identifier: | NCT00263640 |
The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.
Condition | Intervention | Phase |
---|---|---|
Respiratory Hypersensitivity |
Biological: House dust mite, Acaroid |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicentre Randomised Placebo-Controlled Double-Blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum.-Adsorbed Allergoid Preparation of House Dust Mite (D. Pteronyssinus) in Patients With Allergic Bronchial Asthma, Rhinitis, Rhinoconjunctivitis |
Ages Eligible for Study: | 6 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Allergopharma Joachim Ganzer KG | |
Reinbek, Germany, 21465 |
Principal Investigator: | Annemie Narkus, M.D. | Allergopharma Joachim Ganzer KG |
Study ID Numbers: | Al0104av |
Study First Received: | December 8, 2005 |
Last Updated: | July 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00263640 |
Health Authority: | Germany: Paul-Ehrlich-Institut |
House dust mite Bronchial Asthma Allergy House Dust Mite Allergy |
Lung Diseases, Obstructive Hypersensitivity Aluminum sulfate Respiratory Tract Diseases Lung Diseases |
Hypersensitivity, Immediate Asthma Rhinitis Respiratory Hypersensitivity |
Immune System Diseases Bronchial Diseases |